COVID-19-associated optic neuritis – A case series and review of literature
Reads0
Chats0
TLDR
In this article , a series of three patients who developed optic neuritis during the recovery period from corona virus disease-19 infection was presented. And they received intravenous methylprednisolone followed by oral steroids according to the Optic Neuritis Treatment Trail ptotocol.Abstract:
Neuroophthalmic manifestations are very rare in corona virus disease-19 (COVID-19) infection. Only few reports have been published till date describing COVID-19-associated neuroophthalmic manifestations. We, hereby, present a series of three cases who developed optic neuritis during the recovery period from COVID-19 infection. Among the three patients, demyelinating lesions were identified in two cases, while another case was associated with serum antibodies against myelin oligodendrocyte glycoprotein. All three patients received intravenous methylprednisolone followed by oral steroids according to the Optic Neuritis Treatment Trail ptotocol. Vision recovery was noted in all three patients, which was maintained at 2 months of the last follow up visit. read more
Citations
More filters
Journal ArticleDOI
Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis with COVID-19 infection: A case report and literature review
TL;DR: A 35-year-old Thai woman presented with acute blurred vision of her left eye with pain on eye movement for six days and had dry cough for one week before the onset of visual loss as mentioned in this paper .
Journal ArticleDOI
COVID-19 Vaccine-Associated Optic Neuropathy: A Systematic Review of 45 Patients
Ayman G Elnahry,Mutaz Y. Al-Nawaflh,Aisha A. Gamal Eldin,Omar Solyman,Ahmed Sallam,Paul H. Phillips,Abdelrahman M. Elhusseiny +6 more
TL;DR: COVID-19 vaccination may be associated with different forms of optic neuropathy, and patients diagnosed with ON were more likely to be younger and to experience visual improvement.
Journal ArticleDOI
COVID-19 and the risk of CNS demyelinating diseases: A systematic review
TL;DR: Based upon available literature, the rate of CNS demyelinating events occurring in the setting of preceding or concurrent SARS-CoV-2 infection is relatively low considering the prevalence of Sars-CoVsirus 2 infection.
Journal ArticleDOI
Long COVID: Clinical Framing, Biomarkers, and Therapeutic Approaches
Valeria Conti,Graziamaria Corbi,Francesco Sabbatino,Domenico De Pascale,Carmine Sellitto,Berenice Stefanelli,N. Bertini,Matteo De Simone,Luigi Liguori,I di Paola,Maddalena De Bernardo,Angela Tesse,Nicola Rosa,Pasquale Pagliano,Amelia Filippelli +14 more
TL;DR: In this paper , a review aimed to summarize recent evidence on the factors influencing post-COVID-19 syndrome, possible biomarkers, and therapeutic approaches, and suggest a holistic and integrated approach to provide useful guidance for the treatment and overall management of long COVID.
Journal ArticleDOI
Atypical myelin oligodendrocyte glycoprotein antibody–associated optic neuritis and acute demyelinating polyneuropathy after SARS-CoV-2 infection: Case report and literature review
Francesca Bosello,Damiano Marastoni,Francesca B. Pizzini,Chiara Zaffalon,Andrea Zuliani,Giulia Turri,Sara Mariotto,Erika Bonacci,Emilio Pedrotti,Massimiliano Calabrese +9 more
TL;DR: In this article , a 74-year-old patient developed a Myelin Oligodendrocyte Glycoprotein (MOG) antibody-associated unilateral retrobulbar optic neuritis.
References
More filters
Journal ArticleDOI
Angiotensin?converting enzyme 2 (ACE2), SARS?CoV?2 and the pathophysiology of coronavirus disease 2019 (COVID?19)
Arno R. Bourgonje,Amaal Eman Abdulle,Wim Timens,Jan-Luuk Hillebrands,Gerjan Navis,Sanne J. Gordijn,Marieke C. Bolling,Gerard Dijkstra,Adriaan A. Voors,Albert D. M. E. Osterhaus,Peter H. J. van der Voort,Douwe J. Mulder,Harry van Goor +12 more
TL;DR: The role of ACE2 in CO VID‐19 pathophysiology is described, including factors influencing ACE2 expression and activity in relation to COVID‐19 severity, and the relevant pathological changes resulting from SARS‐CoV‐2 infection are discussed.
Journal ArticleDOI
COVID-19 and Eye: A Review of Ophthalmic Manifestations of COVID-19.
TL;DR: A literature search was performed for the publications on ophthalmic manifestations of coronavirus disease-19 (COVID-19) between January 1, 2020 and January 31, 2021 as mentioned in this paper.
Journal ArticleDOI
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis and Myelitis in COVID-19.
TL;DR: A case of a young man presenting with bilateral severe optic neuritis and myelitis, determined to be simultaneously SARS-CoV2 and myelin oligodendrocyte glycoprotein (MOG) IgG antibody positive is described, believed to be the first such case to be reported in the literature.
Journal ArticleDOI
The Optic Neuritis Treatment Trial
TL;DR: The Optic Neuritis Treatment Trial (ONTT) was developed and represents the first multicenter collaborative clinical trial in neuroophthalmology funded by the NEI.
Journal ArticleDOI
COVID-19-Induced Acute Bilateral Optic Neuritis.
TL;DR: A 44-year-old male patient with no past medical history presented 2 weeks after seropositive coronavirus disease 2019 (COVID-19) infection with vision problems suggestive of optic neuritis, who had also anti-MOG antibodies.